The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
The Effectiveness of a 9-Month Regimen of Isoniazid Alone versus 3- and 4-Month Regimens of Isoniazid plus Rifampin for Treatment of Latent Tuberculosis Infection in Children: Results of an 11-Year Randomized Study
Abstract
BACKGROUND: A 9-month course of isoniazid monotherapy is currently recommended for the treatment of latent tuberculosis infection (LTBI) and has been shown to be effective in both children and adults. Reduced compliance with this regimen has forced physicians to explore shorter regimens. The aim of this study was to compare 3- and 4-month combination regimens of isoniazid plus rifampin with a 9-month regimen of isoniazid monotherapy for the treatment of LTBI in children. METHODS: This prospective, randomized, controlled study was conducted over an 11-year period (1995-2005). In period 1 (1995-1998), 232 patients received isoniazid therapy for 9 months (group A), and 238 patients received isoniazid and rifampin for 4 months (group B). In period 2 (1999-2002), 236 patients were treated with isoniazid and rifampin for 4 months (group C), and 220 patients received the same regimen for 3 months (group D). All patients were observed for > or = 3 years. RESULTS: Overall compliance with treatment was good, but patients who received isoniazid monotherapy were less compliant than were those who received short-course combination therapy (P=.011, for group A vs. group B; P=.510, for group C vs. group D). No patient in any group developed clinical disease during the follow-up period. New radiographic findings suggestive of possible active disease were more common in patients who received isoniazid monotherapy (24%) than in those treated with shorter regimens (11.8%, 13.6%, and 11% for groups B, C, and D, respectively; P=.001 for group A vs. group B; P=.418 for group C vs. group D). Serious drug-related adverse effects were not detected. CONCLUSIONS: Short-course treatment with isoniazid and rifampin for 3-4 months is safe and seems to be superior to a 9-month course of isoniazid monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.4.16141 · Cited by 1,525
Bass, J. B., Farer, L. S., Hopewell, P. C., O'Brien, R., Jacobs, R. F., Ruben, F., Snider, D. E., & Thornton, G. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.149.5.8173779 · Cited by 1,193
Controlled chemoprophylaxis trials in tuberculosis. A general review.
Sh, F. (1970) · PubMed · Cited by 721
Iuat (1982) · Bulletin of the World Health Organization · Cited by 515
Control and prevention of tuberculosis in the United Kingdom: Code of Practice 2000
Joint Tuberculosis Committee of the British Thoracic Society (2000) · Thorax · doi:10.1136/thorax.55.11.887 · Cited by 366
Childhood Pulmonary Tuberculosis: Old Wisdom and New Challenges
Marais, B. J., Gie, R. P., Schaaf, H. S., Beyers, N., Donald, P. R., & Starke, J. R. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200511-1809so · Cited by 342
Hong Kong Chest Service/Tuberculosis Research Centre, M. M. R. C. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.1.36 · Cited by 304
How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?
Moulding, T. (2000) · PubMed · Cited by 268
Ena, J., & Valls, V. (2005) · Clinical Infectious Diseases · doi:10.1086/427802 · Cited by 217
Menzies, D., Dion, M.-J., Rabinovitch, B., Mannix, S., Brassard, P., & Schwartzman, K. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-478oc · Cited by 168
Cited by
Getahun, H., Matteelli, A., Abubakar, I., Aziz, M. A., Baddeley, A., Barreira, D., Den Boon, S., Borroto Gutierrez, S. M., Bruchfeld, J., Burhan, E., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01245-2015 · Cited by 596
Mack, U., Migliori, G. B., Sester, M., Rieder, H. L., Ehlers, S., Goletti, D., Bossink, A., Magdorf, K., Hölscher, C., Kampmann, B., et al. (2009) · European Respiratory Journal · doi:10.1183/09031936.00120908 · Cited by 591
Perez-Velez, C. M., & Marais, B. J. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1008049 · Cited by 572
Sterling, T. R., Njie, G., Zenner, D., Cohn, D. L., Reves, R., Ahmed, A., Menzies, D., Horsburgh, C. R., Crane, C. M., Burgos, M., et al. (2020) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6901a1 · Cited by 495
Pediatric Tuberculosis: Global Overview and Challenges
Swaminathan, S., & Rekha, B. (2010) · Clinical Infectious Diseases · doi:10.1086/651490 · Cited by 377
Global tuberculosis drug development pipeline: the need and the reality
Ma, Z., Lienhardt, C., McIlleron, H., Nunn, A. J., & Wang, X. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60359-9 · Cited by 374
Metadata
- Authors
- Spyridis, N. P., Spyridis, P. G., Gelesme, A., Sypsa, V., Valianatou, M., Metsou, F., Gourgiotis, D., & Tsolia, M. N.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-09-15
- Volume
- 45
- Issue
- 6
- Pages
- 715-722
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2146168561
- Cited by
- 259
- References
- 18
- FWCI
- 10.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.